Successful Phase III trial for levomilnacipran ( Pierre Fabre/Forest Labs) in Major Depressive Disorder

Positive top-line results in a Phase III trial showed that treatment with levomilnacipran (F 2695) from Pierre Fabre/Forest Labs. significantly reduced depression symptoms in patients with Major Depressive Disorder compared to placebo, as early as week one.This is the second, positive Phase III study in this population and results from an additional late-stage fixed-dose study are expected in the spring. However, in an earlier Phase III trial, the overall difference observed between the drug-treated and placebo-treated patients was not statistically significant, despite levomilnacipran consistently showing improvement over placebo.